MCC ANALYSIS

Patient ID	00000	**Gender**	NA	**Location**	NA
Patient Name	DUMMY for MCC	**Clinician Name**	Dr. XYZ	**Sample Collected**	DD-MM-YYYY
DOB	DD-MM-YYYY	**GA/LMP Date**	DD-MM-YYYY	**Sample Received**	DD-MM-YYYY
Age	NA	**Hospital Name**	NA	**Report Released**	DD-MM-YYYY

Test Requested:- Maternal cell contamination **Sample Type:- Product of Conception** **Sample Quality:- Acceptable**

CLINICAL INDICATION

NA

RESULTS

No Significant maternal cell contamination was observed in the provided clinical sample as analyzed by STR-based QF-PCR.

METHODOLOGY

Maternal cell contamination is ruled out by PCR-based comparison of short tandem repeat (STR) markers in fetal and maternal samples provided to the laboratory. STR markers included in the analysis are D21S1435, D21S11, D21S1437, D13S634, D18S535, D18S386, D21S1446, D13S305, D18S978, D13S800, D18S390, D13S628, D21S1409, D13S252, D21S1442, D18S819.

LIMITATIONS OF TEST

1. It may not detect structural rearrangements involving the chromosome tested & will not detect abnormalities in any other chromosomes. It may not detect rearrangements including balanced and unbalanced translocation. There could also be error in QF-PCR based on detecting most structural chromosomal anomalies.
2. An aneuploidy test result can only be directly applied to the tissue tested and may not represent the fetal karyotype.
3. The maternal cell contamination assay cannot detect variation in sequences other than the amplified sequences for the whole chromosomes.
4. Although all precautions are taken during any DNA based tests but still the technical error rate for all types of DNA analysis is approximately 2%. So it's important the all the results are interpreted in this context before acting upon these results.
5. The results obtained from these or any other diagnostics kits should be used and interpreted only in the context of the overall clinical picture. Redcliffe Life Sciences cannot accept responsibility for any clinical decisions that are made

DISCLAIMER

The given test result should be interpreted in context of all available clinical findings.
As per the PRE-NATAL DIAGNOSTIC TECHNIQUES (REGULATIONS & PREVENTION OF MISUSE) AMENDMENT ACT 2002, sex determination shall not be done for all prenatal samples.
Redcliffe Life Sciences Pvt. Ltd. is registered in District Gautam Budh Nagar, Uttar Pradesh, India under the Pre-Conception & Pre-Natal Diagnostic Techniques (Prohibition ofSex Selection) Act (PCPNDT Act), 1994 Govt. of India;vide Reg No. GBN/336

928-909-0609 care@redcliffelabs.com redcliffelabs.com

REFERENCES

1. Schrijver, Iris, Sarah C. Cherny, and James L. Zehnder. "Testing for maternal cell contamination in prenatal samples: a comprehensive survey of current diagnostic practices in 35 molecular diagnostic laboratories." The Journal of Molecular Diagnostics 9, no. 3 (2007): 394-400.

2. American College of Medical Genetics-Standards and Guidelines for Clinical Genetics Laboratories, 2006 Edition.

3. Nagan, Narasimhan, Nicole E. Faulkner, Christine Curtis, and Iris Schrijver. "Laboratory guidelines for detection, interpretation, and reporting of maternal cell contamination in prenatal analyses: a report of the association for molecular pathology." The Journal of Molecular Diagnostics 13, no. 1 (2011): 7-11.

4. Steinberg, S., Sara Katsanis, A. Moser, and G. Cutting. "Biochemical analysis of cultured chorionic villi for the prenatal diagnosis of peroxisomal disorders: biochemical thresholds and molecular sensitivity for maternal cell contamination detection." Journal of medical genetics 42, no. 1 (2005): 38-44.

5. Langlois S, Duncan A; SOGC GENETICS COMMITTEE; CCMG PRENATAL DIAGNOSIS COMMITTEE. Use of a DNA method, QF-PCR,in the prenatal diagnosis of fetal aneuploidies. J Obstet Gynaecol Can. 2011 Sep;33(9):955-960.

6. Phan, T. Quantitative Fluorescent Polymerase Chain Reaction for Prenatal Diagnosis and Its Application in Vietnam: A Literature Review. Preprints 2021, 2021060285.

Important: On doing PNDT test, the undersigned hereby confirms that no sex chromosome information has been passed on to anyone in whatsoever manner.

Disclaimer- The sample is processed at the PC-PNDT certified laboratory

Disclaimer: Method given in report are only indicative and can be changed depending upon type of machine and kit available at time of testing.

Not all tests at all locations are under NABL scope. Availability of tests under NABL scope varies from lab to lab.

Mr. Nakul Mohan
Senior Executive
MSc Biotechnology

Dr. Himani Pandey
Lab Head - Genomics
Post-Doc.Fellowship
(Medical Genetics),SGPGIMS

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.

2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.

3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.

4. This report shall not be deemed valid or admissible for any medico-legal purposes.

5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.